Tatyana Feldman

11.5k total citations
159 papers, 2.0k citations indexed

About

Tatyana Feldman is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Tatyana Feldman has authored 159 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 123 papers in Pathology and Forensic Medicine, 91 papers in Oncology and 46 papers in Genetics. Recurrent topics in Tatyana Feldman's work include Lymphoma Diagnosis and Treatment (122 papers), CAR-T cell therapy research (50 papers) and Chronic Lymphocytic Leukemia Research (45 papers). Tatyana Feldman is often cited by papers focused on Lymphoma Diagnosis and Treatment (122 papers), CAR-T cell therapy research (50 papers) and Chronic Lymphocytic Leukemia Research (45 papers). Tatyana Feldman collaborates with scholars based in United States, Canada and United Kingdom. Tatyana Feldman's co-authors include André Goy, Stephen M. Ansell, Nancy L. Bartlett, Ranjana H. Advani, Radhakrishnan Ramchandren, Anthony R. Mato, Alex F. Herrera, Julie M. Vose, Alison J. Moskowitz and Craig H. Moskowitz and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Tatyana Feldman

142 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tatyana Feldman United States	23	1.5k	1.3k	463	450	422	159	2.0k
Dirk Huebner United States	15	1.4k 0.9×	1.1k 0.9×	261 0.6×	499 1.1×	330 0.8×	44	1.8k
Andy I. Chen United States	14	829 0.6×	797 0.6×	552 1.2×	284 0.6×	278 0.7×	38	1.5k
Luís Colomo Spain	25	1.9k 1.3×	1.6k 1.3×	779 1.7×	317 0.7×	501 1.2×	66	2.7k
Marco Fizzotti Italy	17	1.4k 0.9×	876 0.7×	459 1.0×	287 0.6×	479 1.1×	38	2.0k
Daisuke Ennishi Japan	20	958 0.6×	656 0.5×	253 0.5×	263 0.6×	452 1.1×	109	1.5k
Jocelyn Maragulia United States	16	993 0.7×	581 0.5×	287 0.6×	465 1.0×	325 0.8×	37	1.3k
Stephanie Sasse Germany	23	753 0.5×	819 0.6×	624 1.3×	258 0.6×	153 0.4×	48	1.6k
D M Knowles United States	18	1.1k 0.8×	1.0k 0.8×	380 0.8×	242 0.5×	598 1.4×	23	1.9k
Deepika Cattry United States	3	906 0.6×	2.2k 1.7×	1.2k 2.7×	244 0.5×	311 0.7×	4	2.7k
Kenneth MacLennan United Kingdom	20	988 0.7×	712 0.6×	381 0.8×	200 0.4×	237 0.6×	43	1.6k

Countries citing papers authored by Tatyana Feldman

Since Specialization

Citations

This map shows the geographic impact of Tatyana Feldman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tatyana Feldman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tatyana Feldman more than expected).

Fields of papers citing papers by Tatyana Feldman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tatyana Feldman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tatyana Feldman. The network helps show where Tatyana Feldman may publish in the future.

Co-authorship network of co-authors of Tatyana Feldman

This figure shows the co-authorship network connecting the top 25 collaborators of Tatyana Feldman. A scholar is included among the top collaborators of Tatyana Feldman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tatyana Feldman. Tatyana Feldman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ahn, Jaeil, Brittany Sinclaire, Christina Cho, et al.. (2025). Real-World Outcomes of Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Third-Line Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Single-Center Study. SHILAP Revista de lepidopterología. 6(1). 3–3. 1 indexed citations

Schett, Georg, Tatyana Feldman, Jeremy S. Abramson, et al.. (2024). P105 NEX-T CD19 chimeric antigen receptor (CAR) T-cell therapy CC-97540 (BMS-986353): Preclinical and translational evidence of deep B-cell depletion suitable for study in severe refractory autoimmune diseases. SHILAP Revista de lepidopterología. A115–A116. 2 indexed citations

Vose, Julie M., Chan Y. Cheah, Michael Roost Clausen, et al.. (2024). 3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma. Blood. 144(Supplement 1). 4480–4480. 8 indexed citations

Maakaron, Joseph, Dipenkumar Modi, Matthew Mei, et al.. (2024). Investigating the Novel Combination of the Innate Cell Engager (ICE®) Acimtamig with Off-the-Shelf Allogeneic Natural Killer Cells AlloNK® in Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Initial Results of the Phase 2 Luminice-203 Study. Blood. 144(Supplement 1). 3052–3052. 2 indexed citations

Chu, Paul K., et al.. (2024). Bruton’s tyrosine kinase inhibitor associated localized extremity edema and erythema. JAAD Case Reports. 54. 93–97. 1 indexed citations

Feldman, Tatyana, et al.. (2023). Retrospective Review of Patients Treated with Intrathecal Rituximab for Primary and Secondary CNS Lymphoma and Leukemia. Blood. 142(Supplement 1). 1773–1773.

Soong, David S., Catherine Thiéblemont, John Karavitis, et al.. (2023). Evaluation of ctDNA in a phase I/II trial in relapsed or refractory large B‐cell lymphoma of epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T‐cell–engaging antibody. Hematological Oncology. 41(S2). 326–328. 2 indexed citations

Nastoupil, Loretta J., Manali Kamdar, Julio C. Chávez, et al.. (2023). LISOCABTAGENE MARALEUCEL (LISO‐CEL) VERSUS STANDARD OF CARE (SOC) AS SECOND‐LINE THERAPY IN LARGE B‐CELL LYMPHOMA (TRANSFORM STUDY): SUBGROUP ANALYSES BY PRIOR THERAPY RESPONSE. Hematological Oncology. 41(S2). 212–214.

Feghali, Karine A. Al, Lydia Pascual, Michael Marafelias, et al.. (2023). Prevalence of Non-Hodgkin Lymphoma Patients at High Risk of Failure after CAR T-Cell Therapy Eligible for Bridging Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics. 117(2). e463–e464.

10.

Strati, Paolo, Tatyana Feldman, Christiane Querfeld, et al.. (2023). Phase 1 Study of Autologous Sirpα-Low Macrophages (SIRPant-M) Administered By Intratumoral Injection Alone or in Combination with External-Beam Radiotherapy in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma (NCT05967416). Blood. 142(Supplement 1). 4856–4856. 1 indexed citations

11.

Advani, Ranjana H., Alison J. Moskowitz, Nancy L. Bartlett, et al.. (2021). Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood. 138(6). 427–438. 116 indexed citations

12.

Ip, Andrew, Anthony R. Mato, Nicholas P. Howard, et al.. (2020). COVID-19 Impact on Lymphoma Patients' Clinical Outcomes - an Observational Cohort Study. Blood. 136(Supplement 1). 6–7. 5 indexed citations

13.

Ramchandren, Radhakrishnan, Ranjana H. Advani, Stephen M. Ansell, et al.. (2019). Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. Clinical Cancer Research. 25(6). 1718–1726. 30 indexed citations

14.

Phillips, Adrienne A., Paul Fields, Olivier Hermine, et al.. (2019). Mogamulizumab versus investigator’s choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma. Repositorio Académico USMP. 5 indexed citations

15.

Herrera, Alex F., Alison J. Moskowitz, Nancy L. Bartlett, et al.. (2017). Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 131(11). 1183–1194. 230 indexed citations

16.

Ramchandren, Radhakrishnan, Michelle A. Fanale, Antonio Rueda, et al.. (2017). Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 Study. Blood. 130(Suppl_1). 651–651. 22 indexed citations

17.

Goy, André, Tatyana Feldman, Lori A. Leslie, et al.. (2017). Phase Ib-II Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib, w/ Lenalidomide and Rituximab in Relapsed / Refractory Mantle Cell Lymphoma. Blood. 130. 2785–2785. 1 indexed citations

18.

Howlett, Christina, Sonya J. Snedecor, Daniel J. Landsburg, et al.. (2015). Front‐line, dose‐escalated immunochemotherapy is associated with a significant progression‐free survival advantage in patients with double‐hit lymphomas: a systematic review and meta‐analysis. British Journal of Haematology. 170(4). 504–514. 113 indexed citations

19.

Donato, Michèle L., Themba Nyirenda, David H. Vesole, et al.. (2013). Donor CD3 Chimerism After Allogeneic Transplantation Predicts Probability Of Relapse For Patients Treated For Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), and Non-Hodkgin's Lymphoma (NHL). Blood. 122(21). 4545–4545. 1 indexed citations

20.

Feldman, Tatyana, Kar Fai Chow, Anthony R. Mato, et al.. (2013). PEG-Asparaginase Based Multidrug Chemotherapy is Effective for Refractory Disseminated Extranodal NK/T-Cell Lymphoma With Leptomentigeal Involvement: A Clinical Case Report and Review of Literature. 2(1). 31–36. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact